Opus Genetics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Opus Genetics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Mar 21, 2014 |
| FY2013 | Dec 31, 2012 | $0 | Mar 21, 2014 |
| FY2011 | Dec 31, 2011 | $0 | Mar 16, 2012 |
| FY2011 | Dec 31, 2010 | $0 | Mar 16, 2012 |
| FY2011 | Dec 31, 2009 | $0 | Mar 16, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.20M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $10.99M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $19.05M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $39.85M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $589.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $0 | Mar 24, 2022 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($49.59M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($57.53M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($9.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $17.89M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($56.69M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($24.62M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($6.17M) | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | ($3.12M) | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | ($5.34M) | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | ($3.84M) | Mar 7, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($38.60M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($62.07M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($10.56M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $18.23M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($22.71M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($19.97M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($4.19M) | Mar 11, 2021 |
| FY2018 | Dec 31, 2018 | ($4.97M) | Mar 7, 2019 |
| FY2018 | Sep 30, 2018 | ($4.68M) | Mar 7, 2019 |
| FY2018 | Jun 30, 2018 | ($5.00M) | Mar 7, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $5.48M | Feb 21, 2020 |
| FY2019 | Dec 31, 2018 | $13.11M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $10.72M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $10.09M | Mar 9, 2018 |
| FY2017 | Dec 31, 2015 | $12.15M | Mar 9, 2018 |
| FY2016 | Dec 31, 2014 | $7.02M | Feb 24, 2017 |
| FY2015 | Dec 31, 2013 | $3.25M | Mar 14, 2016 |
| FY2013 | Dec 31, 2012 | $3.39M | Mar 21, 2014 |
| FY2012 | Dec 31, 2011 | $11.99M | Mar 22, 2013 |
| FY2011 | Dec 31, 2010 | $3.93M | Mar 16, 2012 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($35.25M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($25.58M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($1.11M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $14.31M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($19.37M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($6.80M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($3.59M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($18.84M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($15.42M) | Mar 7, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $0 | Mar 11, 2021 |
| FY2020 | Dec 31, 2019 | $25.0K | Mar 11, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.24M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $36.86M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $53.95M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $48.99M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $26.08M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $17.68M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $1.78M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $16.04M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $28.29M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $21.04M | Mar 9, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.90M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $11.30M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $4.04M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.75M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $3.86M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $31.15M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | $9.34M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | $5.48M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $11.52M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | $3.99M | Mar 9, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $15.35M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $6.72M | Mar 12, 2026 |
| FY2025 | Dec 31, 2023 | $49.91M | Mar 12, 2026 |
| FY2024 | Dec 31, 2022 | $46.24M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $22.22M | Mar 8, 2024 |
| FY2022 | Dec 31, 2020 | ($13.47M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | ($7.56M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2018 | ($1.70M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2017 | $16.77M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $17.06M | Mar 7, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($188.59M) | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | ($139.00M) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | ($81.47M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($71.48M) | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | ($89.37M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($32.68M) | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | ($8.06M) | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | ($154.69M) | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | ($140.32M) | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | ($115.02M) | Mar 9, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $45.09M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | $30.32M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | $50.50M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $42.63M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | $24.53M | Mar 30, 2023 |
| FY2018 | Dec 31, 2018 | $8.74M | Mar 7, 2019 |
| FY2018 | Dec 31, 2017 | $8.90M | Mar 7, 2019 |
| FY2018 | Dec 31, 2016 | $11.58M | Mar 7, 2019 |
| FY2017 | Dec 31, 2015 | $10.20M | Mar 9, 2018 |
| FY2017 | Dec 31, 2014 | $9.83M | Mar 9, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 24, 2022 |
| FY2018 | Dec 31, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Mar 7, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | (2) | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | (5) | Mar 24, 2022 |
| FY2018 | Dec 31, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 7, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Mar 7, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 69.89M | Mar 12, 2026 |
| FY2025 | Dec 31, 2024 | 31.57M | Mar 12, 2026 |
| FY2024 | Dec 31, 2023 | 23.98M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 20.86M | Mar 8, 2024 |
| FY2022 | Dec 31, 2021 | 18.85M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 10.88M | Mar 24, 2022 |
| FY2020 | Dec 31, 2019 | 2.85M | Mar 11, 2021 |
| FY2019 | Dec 31, 2018 | 3.12M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | 31.73M | Mar 7, 2019 |
| FY2017 | Dec 31, 2016 | 23.74M | Mar 9, 2018 |